PARP inhibition in UV-associated angiosarcoma preclinical models.

Marije E WeidemaIngrid M E DesarMelissa H S Hillebrandt-RoeffenAnke E M van ErpMikio Masuzawanull nullUta E FluckeWinette T A van der GraafYvonne M H Versleijen-Jonkers

Published in: Journal of cancer research and clinical oncology (2021)

We showed combination treatment of olaparib with TMZ was synergistic in UV AS cell lines. Expression of PARP1 and SLFN11 was present in the majority of UV AS tumor samples. Together, these results suggest combination treatment of olaparib and TMZ is a potential novel AS subtype-specific treatment option for UV AS patients.

Keyphrases

poor prognosis
newly diagnosed
ejection fraction
stem cells
dna repair
end stage renal disease
prognostic factors
combination therapy
bone marrow
risk assessment
binding protein